Apotex breaks ground on new FDA generics track

9 August 2018
drugs_pills_tablets_big

Apotex's potassium chloride has become the first generic drug to be granted Competitive Generic Therapy designation by the US Food and Drug Administration (FDA).

The new designation is designed to expedite the approval process for certain generic drugs, in accordance with FDA Commissioner Scott Gottlieb's longstanding push for increased access to generic and biosimilar therapies.

A drug may receieve the designation if there is only one equivalent therapy already FDA-approved, or if there are none at all. In the case of a generic product being first to market, meeting certain conditions may result in the FDA granting the manufacturer 180 days of market exclusivity. Apotex's potassium chloride has been granted exclusivity, but if it has not launched within 75 days of its approval it will forfeit that privilege.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics